Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer

Daniel A. Hamstra, MD, PhD
Published: Monday, Jan 11, 2016



Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing different lengths of radiation treatments for patients with prostate cancer.

The RTOG 0145 study compared an 8-week to 5.5-week regimen of radiation therapy in more than 1000 patients with prostate cancer, Hamstra explains. Outcomes were found to be identical regarding tumor recurrence and short- and long-term side effects, with a small increase in gastrointestinal-related effects in the longer regimen.

In the CHIP trial, more than 3000 patients from the United Kingdom were randomized to receive either an 8-week regimen, 19 treatments, or 20 treatments. In the 20-treatment arm, outcomes were reported to be similar in comparison to the 8-week regimen arm.

<<< View more from the 2016 GU Cancer Symposium



Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing different lengths of radiation treatments for patients with prostate cancer.

The RTOG 0145 study compared an 8-week to 5.5-week regimen of radiation therapy in more than 1000 patients with prostate cancer, Hamstra explains. Outcomes were found to be identical regarding tumor recurrence and short- and long-term side effects, with a small increase in gastrointestinal-related effects in the longer regimen.

In the CHIP trial, more than 3000 patients from the United Kingdom were randomized to receive either an 8-week regimen, 19 treatments, or 20 treatments. In the 20-treatment arm, outcomes were reported to be similar in comparison to the 8-week regimen arm.

<<< View more from the 2016 GU Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x